Kiromic
Business Services · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7707 Fannin St Ste 140, Houston, Texas, ...Phone Number
(832) 968-4888Website
www.kiromic.comRevenue
<$5 MillionStock Symbol
KRBPIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Kiromic
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) platform to discover, validate and develop celland gene therapies with a therapeutic focus on immuno-oncology. Kiromic is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell therapy platform that exploits the natural potency of gamma delta T-cells to target solid cancers. Kiromic's DIAMOND AI is where data science meets target identification to dramatically compress the years and millions of dollars required to develop a cellular therapeutic. The Company maintains offices in Houston, Texas.Explore more
Popular SearchesKiromicKiromic BiopharmaKiromic Biopharma IncKiromic LLCKiromic IncSIC Code 87,873NAICS Code 54,541Ticker OTC: KRBPShow moreKiromic Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Kiromic your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Kiromic
Check out if Kiromic is spiking on competitors!
Click to see if Kiromic had a recent Job posting/layoffs
Kiromic, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Kiromic recently announced quarterly report
Product Launch: Get notified when Kiromic launches new products
Funding: Get notified immidiatlly once Kiromic has new funding data
Check if Kiromic has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Kiromic
Compare insights from companies similar to Kiromic, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Kiromic is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Kiromic is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Kiromic.
Kiromic financials insights
Gather financial insights about Kiromic, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Stock Offering
$15M
Kiromic Tech Stack
A closer look at the technologies used by Kiromic
Most Recent Scoops
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Person-Based
Project
Product Development, Medical Research, Pharmaceuticals, Clinical Operations
Earnings
Product Development
Kiromic News & Media
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
HOUSTON--(BUSINESS WIRE)---- $KRBP--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic or locally-advanced non-small cell lung cancer (NSKiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
HOUSTON--(BUSINESS WIRE)---- $KRBP--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable efficacy results from the 12-month follow-up visit for the first patient and the two-month follow-up visit for the seventh patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides an enrollment update. This trial is evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic orKiromic BioPharma Reports 32% Decrease in Tumor Volume Eight Months Post-Treatment in Fourth Patient Enrolled in Deltacel-01
HOUSTON--(BUSINESS WIRE)---- $KRBP--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) reports favorable ongoing efficacy results from the eight-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical trial, and provides additional updates on the first and seventh patients. This trial is evaluating Deltacel™ (KB-GDT-01), the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell (GDT) therapy, in patients with stage 4 metastatic non-small cell lKiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
HOUSTON--(BUSINESS WIRE)---- $KRBP--Kiromic BioPharma, Inc. (OTCQB: KRBP) (“Kiromic” or the “Company”) today announced that it has entered into a settlement agreement with the U.S. Securities and Exchange Commission (the “SEC”), resolving the previously disclosed SEC investigation arising from the non-disclosure by Kiromic’s prior executive management of the clinical holds placed on the investigational new drug (“IND”) applications the Company filed with the U.S. Food and Drug Administration (th
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Kiromic
Sign Up For FreeTo access detailed company insights
Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND AI (artificial intelligence) platform to discover, validate and develop celland gene therapies with a therapeutic focus on immuno-oncology. Kiromic is in the process of developing ALEXIS, a multi-indication allogeneic CAR-T cell thera... Read More
